Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01436474 · ClinicalTrials.gov registry record · Phase 1

Pilot Study of Varenicline to Treat Opioid Dependence

A Phase 1 study, sponsored by Mayo Clinic.

Completed
Registry status
Phase 1
Development phase
21
Enrollment target

NCT01436474: Completed Phase 1 study, sponsored by Mayo Clinic.

NCT01436474 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01436474, a Phase 1 study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 1
Development phase
21 participants
Enrollment target

Study Summary

The objective of this proposal is to explore the potential of varenicline as a pharmacotherapeutic agent for opioid dependence and addiction.

Primary Outcome

During their treatment, patients are closely monitored by a multidisciplinary team, and there are regular assessments of pain, depression, substance use, and pain-related physical and emotional functioning

Interventions

  • DRUG Placebo
  • DRUG Varenicline

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2011-06
Est. Completion 2012-12
Phase Phase 1
Mayo Clinic

2,844 total trials

What the finished NCT01436474 record still lists

NCT01436474 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01436474 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01436474 about?

NCT01436474 is a clinical study titled "Pilot Study of Varenicline to Treat Opioid Dependence". The objective of this proposal is to explore the potential of varenicline as a pharmacotherapeutic agent for opioid dependence and addiction.

What is the current status of trial NCT01436474?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2011-06. Estimated completion is 2012-12.

What interventions are being tested in trial NCT01436474?

The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG).

Who is sponsoring clinical trial NCT01436474?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01436474's enrollment target sits among peer trials

21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01436474, the US trial registry maintained by the National Library of Medicine. NCT01436474 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.